Niagen Bioscience, Inc. SEC filings NAGE
Niagen Bioscience, Inc. has 981 filings in SEC EDGAR's recent list, going back to Jan 18, 2007. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 24, 2026 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Apr 25, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 19, 2023 | — |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 16, 2022 |
| DEFA14A | Additional proxy material | Apr 21, 2021 | — |
| DEF 14A | Proxy statement | Apr 21, 2021 | Jun 17, 2021 |
| DEFA14A | Additional proxy material | Apr 21, 2020 | — |
| DEF 14A | Proxy statement | Apr 21, 2020 | Jun 19, 2020 |
| DEFA14A | Additional proxy material | Apr 23, 2019 | — |
| DEF 14A | Proxy statement | Apr 23, 2019 | Jun 21, 2019 |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 22, 2018 |
| DEFA14A | Additional proxy material | Jun 20, 2017 | — |
| DEF 14A | Proxy statement | Jun 20, 2017 | Aug 10, 2017 |
| PRE 14A | Preliminary proxy statement | Jun 9, 2017 | Jun 9, 2017 |
| DEFA14A | Additional proxy material | May 1, 2017 | — |
| DEF 14A | Proxy statement | May 1, 2017 | Jun 20, 2017 |
| DEFA14A | Additional proxy material | May 16, 2016 | — |
| DEFA14A | Additional proxy material | Apr 12, 2016 | — |
| DEF 14A | Proxy statement | Apr 12, 2016 | Jun 2, 2016 |
| DEFA14A | Additional proxy material | Apr 16, 2015 | — |
| DEF 14A | Proxy statement | Apr 16, 2015 | Jun 6, 2015 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2015 | Apr 1, 2015 |
| DEF 14A | Proxy statement | Jul 27, 2012 | Aug 28, 2012 |
| DEF 14A | Proxy statement | Sep 13, 2011 | Sep 13, 2011 |
| PRE 14A | Preliminary proxy statement | Aug 29, 2011 | Aug 29, 2011 |
| DEF 14A | Proxy statement | Apr 11, 2011 | May 10, 2011 |
| DEF 14A | Proxy statement | May 4, 2010 | May 20, 2010 |
| PRE 14A | Preliminary proxy statement | Apr 23, 2010 | May 20, 2010 |
| DEF 14A | Proxy statement | Apr 16, 2009 | May 13, 2009 |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NAGE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1386570
- Former names
- ChromaDex Corp. (until Mar 10, 2025); CODY RESOURCES, INC. (until Jun 24, 2008)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.